Use of cannabinoids as a therapeutic perspective for psoriasis vulgaris: an integrative review
DOI:
https://doi.org/10.33448/rsd-v11i15.37568Keywords:
Cannabidiol; Cannabis; Psoriasis.Abstract
Psoriasis is a chronic pathology with rapid proliferation in the skin, it is not contagious and shows signs of inflammation. In it, the immune system attacks the cells of the dermis, and for this reason it is an autoimmune disease favoring the appearance of scaly lesions, with the presence of erythema and irregular shapes. Considering this, this integrative literature review aims to understand the use of the Cannabis sativa plant as a therapeutic perspective for psoriasis vulgaris. For this, a search on the subject was carried out in the Scientific Electronic Library Online (SciELO), U.S National Library of Medicine National Institutes of Health (PubMed) and Academic Google databases, the inclusion rules were: text available in its entirety; articles published in the last decade, prioritizing the most recent ones; written in Portuguese, English or Spanish and, finally, be directly related to the object of study presented here. It was found that cannabinoids have great potential in the treatment of psoriasis, with their mechanism of action focused on the main pathogenic pathways of the disease: keratogenesis, inflammation and angiogenesis, however studies are mostly in vitro. More clinical trials in humans and studies are needed to clarify the toxicity, safety and efficacy of cannabinoids in the treatment of the disease in question.
References
Barros, B., Casanova, L., Nascimento, L. B., & Coutinho, M. (2021). Plantas e produtos de origem vegetal no tratamento da psoríase: potencial terapêutico e inovação na área. Infarma - Ciências Farmacêuticas. 33. 231. https://doi.org/10.14450/2318-9312.v33.e3.a2021.pp231-246.
Baswan, S. M., Klosner, A. E., Glynn, K., Rajgopal, A., Malik, K., Yim, S., & Stern, N. (2020). Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clinical, cosmetic and investigational dermatology, 13, 927–942. https://doi.org/10.2147/CCID.S286411.
Castilho, A. C. S., Lopes, C. de O. P., & Salles, B. C. C. (2021). Fisiopatologia da psoríase e seus aspectos imunológicos: uma revisão sistemática. Research, Society and Development, 10(11), e256101119346. https://doi.org/10.33448/rsd-v10i11.19346
Conrad, C., & Gilliet, M. (2018). Psoriasis: from Pathogenesis to Targeted Therapies. Clinical reviews in allergy & immunology, 54(1), 102–113. https://doi.org/10.1007/s12016-018-8668-1.
Costa, J. S., & Lazzaretti, C. (2019). PSORÍASE: UMA REVISÃO DOS MECANISMOS FISIOPATOLÓGICOS DA DOENÇA. INSTITUTO FEDERAL DE EDUCAÇÃO, CIÊNCIA E TECNOLOGIA DO RIO GRANDE DO SUL, 66.
Di Marzo, V., & Piscitelli, F. (2015). The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics, 12(4), 692–698. https://doi.org/10.1007/s13311-015-0374-6.
Friedman, A. J., Momeni, K., & Kogan, M. (2021). Topical Cannabinoids for the Management of Psoriasis Vulgaris: Report of a Case and Review of the Literature. Journal of drugs in dermatology : JDD, 19(8), 795. https://doi.org/10.36849/JDD.2020.5229
Gęgotek, A., Atalay, S., Wroński, A., Markowska, A., & Skrzydlewska, E. (2021). Cannabidiol Decreases Metalloproteinase Activity and Normalizes Angiogenesis Factor Expression in UVB-Irradiated Keratinocytes from Psoriatic Patients. Oxidative medicine and cellular longevity, 2021, 7624389. https://doi.org/10.1155/2021/7624389.
Grant, M. J., & Booth, A. (2009). A typology of reviews: na analysis of 14 review types and associated methodologies. Health Info Libr J. 26(2), 91-108. https://doi.org/10.1111/j.1471-1842.2009.00848.x.
Guedes, D. R., & Ferreira, S. C. (2020). A trajetória de uma vida marcada pelo preconceito e exclusão social em decorrência do estigma da Psoríase: Relato de caso. Research, Society and Development, 9(10), e7889109107. https://doi.org/10.33448/rsd-v9i10.9107.
Jarocka-Karpowicz, I., Biernacki, M., Wroński, A., Gęgotek, A., & Skrzydlewska, E. (2020). Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris. Biomolecules, 10(3), 367. https://doi.org/10.3390/biom10030367
Jastrząb, A., Gęgotek, A., & Skrzydlewska, E. (2019). Cannabidiol Regulates the Expression of Keratinocyte Proteins Involved in the Inflammation Process through Transcriptional Regulation. Cells, 8(8), 827. https://doi.org/10.3390/cells8080827.
Lima, B. S. B., Cunha, M. A. A., & Oliveira, M. S. (2013). Aspectos Imunopatológicos da Psoríase. Proceedings of Safety, Health and Environment World Congress. 13, 116-119. doi: 10.14684/SHEWC.13.2013.115-118.
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021). The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. International journal of molecular sciences, 22(17), 9472. https://doi.org/10.3390/ijms22179472.
Łuczaj, W., Dobrzyńska, I., Wroński, A., Domingues, M. R., Domingues, P., & Skrzydlewska, E. (2020). Cannabidiol-Mediated Changes to the Phospholipid Profile of UVB-Irradiated Keratinocytes from Psoriatic Patients. International journal of molecular sciences, 21(18), 6592. https://doi.org/10.3390/ijms21186592.
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., Sharkey, K. A., & Zimmer, A. (2015). Endocannabinoid signaling at the periphery: 50 years after THC. Trends in pharmacological sciences, 36(5), 277–296. https://doi.org/10.1016/j.tips.2015.02.008.
Martins, A. M., Gomes, A. L., Vilas Boas, I., Marto, J., & Ribeiro, H. M. (2022). Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review. Pharmaceuticals, 15(2), 210. https://doi.org/10.3390/ph15020210.
Meneguin, S., de Godoy, N. A., Pollo, C. F., Miot, H. A., & Oliveira, C. (2020). Quality of life of patients living with psoriasis: a qualitative study. BMC dermatology, 20(1), 22. https://doi.org/10.1186/s12895-020-00116-9.
Milando, R., & Friedman, A. (2019). Cannabinoids: Potential Role in Inflammatory and Neoplastic Skin Diseases. American journal of clinical dermatology, 20(2), 167–180. https://doi.org/10.1007/s40257-018-0410-5.
Narouze, S. N. (2021). Cannabinoids and Pain. Cuyahoga Falls, USA: Springer.
Norooznezhad, A. H., & Norooznezhad, F. (2017). Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Medical hypotheses, 99, 15–18. https://doi.org/10.1016/j.mehy.2016.12.003.
Pagano, E., Iannotti, F. A., Piscitelli, F., Romano, B., Lucariello, G., Venneri, T., Di Marzo, V., Izzo, A. A., & Borrelli, F. (2021). Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. Phytotherapy research: PTR, 35(1), 517–529. https://doi.org/10.1002/ptr.6831.
Palmieri, B., Laurino, C., & Vadalà, M. (2019). A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. La Clinica terapeutica, 170(2), e93–e99. https://doi.org/10.7417/CT.2019.2116
Puaratanaarunkon, T., Sittisaksomjai, S., Sivapornpan, N., Pongcharoen, P., Chakkavittumrong, P., Ingkaninan, K., Temkitthawon, P., Promgool, T., Waranuch, N., & Asawanonda, P. (2022). Topical cannabidiol-based treatment for psoriasis: A dual-centre randomized placebo-controlled study. Journal of the European Academy of Dermatology and Venereology: JEADV, 36(9), e718–e720. https://doi.org/10.1111/jdv.18215.
Ramot, Y., Sugawara, K., Zákány, N., Tóth, B. I., Bíró, T., & Paus, R. (2013). A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ. PeerJ, 1, e40. https://doi.org/10.7717/peerj.40.
Rodrigues J. M. C., Gandra M. F., dos Santos I. X. P., Barbosa H. C. D., Acciarito M. F. T. G., Oliveira J. R. A., Souza I. H. de, Guimarães I. S., Elias L. L. de O., & Franco E. L. (2020). Estresse e psoríase: novas abordagens no tratamento. Revista Eletrônica Acervo Científico, 12, e4638. https://doi.org/10.25248/reac.e4638.2020.
Scheau, C., Badarau, I. A., Mihai, L. G., Scheau, A. E., Costache, D. O., Constantin, C., Calina, D., Caruntu, C., Costache, R. S., & Caruntu, A. (2020). Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules (Basel, Switzerland), 25(3), 652. https://doi.org/10.3390/molecules25030652.
Shao, K., Stewart, C., & Grant-Kels, J. M. (2021). Cannabis and the skin. Clinics in dermatology, 39(5), 784–795. https://doi.org/10.1016/j.clindermatol.2021.05.006.
Soares, M. G. S., Silva, M. E. W. B., Barbosa, M. L. C. S., Macêdo, L. P., Júnior, F. J. S. S., Costa, A. C. A., & Soares, L. L. (2022). O uso de canabinoides em fisiopatologias dermatológicas: uma revisão sistemática. Research, Society and Development, 11(2), e55411225961-e55411225961.
Tammaro, A., Magri, F., Chello, C., Giordano, D., Parisella, F. R., De Marco, G., & Persechino, S. (2019). A successful topical treatment for cutaneous inflammatory diseases:an additional or alternative therapy to topical steroids. European annals of allergy and clinical immunology, 51(3), 129–130. https://doi.org/10.23822/EurAnnACI.1764-1489.79.
Vincenzi, C., & Tosti, A. (2020). Efficacy and Tolerability of a Shampoo Containing Broad-Spectrum Cannabidiol in the Treatment of Scalp Inflammation in Patients with Mild to Moderate Scalp Psoriasis or Seborrheic Dermatitis. Skin appendage disorders, 6(6), 355–361. https://doi.org/10.1159/000510896.
Wilkinson, J. D., & Williamson, E. M. (2017). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of dermatological science, 45(2), 87–92. https://doi.org/10.1016/j.jdermsci.2006.10.009.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Laura Martins da Silva; Uiara Maria de Barros Lira Lins; Ednaldo de Santana Souza; Salatiel Henrique Pereira de Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
